G1 Therapeutics — Investor Presentation (November 2017)
42 slides from G1 Therapeutics's investor presentation, Nov 13, 2017
Slide 1: G1 Therapeutics, November 2017
79 T.W. Alexander Drive | 4501 Research Commons, Suite 100 | Research Triangle Park, NC 27709 919-213-9835 (P) | 919-741-5830 (F) | www.g1therapeutics.com November 2017 1
Slide 2: Forward-looking statements
Forward-looking statements This presentation and the accompanying oral commentary contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, known as the PSLRA, that are based on our beliefs and assumptions and on information available to us as o
Slide 3: G1 Therapeutics: clinical-stage oncology company
G1 Therapeutics: clinical-stage oncology company Advancing the validated CDK4/6 inhibitor space Three wholly owned drug candidates addressing distinct multi-billion dollar markets Trilaciclib is first-in-class with compelling clinical data; currently in four Phase 2 trials G1T38 has best-in-class po
Slide 4: Experienced leadership, well financed
Experienced leadership, well financed Management team Proven industry leaders with more than 75 years of oncology experience Mark Velleca, MD, PhD – Chief Executive Officer Raj Malik, MD – Chief Medical Officer Terry Murdock – SVP Development Operations Buck Phillips – CFO, SVP Corporate Development
Slide 5: CDK4/6 is a validated and promising target
CDK4/6 is a validated and promising target From: Nat Rev Drug Disc 2015;14:130-146 Nobel Prize-winning science FDA approval of Ibrance in 2015, Kisqali and Verzenio in 2017 ~ $11 billion estimated global peak sales in breast cancer alone Significant therapeutic and market potential in multiple other
Slide 6: CDK4/6 typically required for cell cycle progression
CDK4/6 typically required for cell cycle progression To grow and proliferate, all cells progress through four phases of the cell cycle G1 and G2 are gap or growth phases S phase: DNA synthesis M phase: cell division 6
Slide 7: Selective CDK4/6 inhibition arrests cells in G1
Selective CDK4/6 inhibition arrests cells in G1 Selective CDK4/6 inhibition blocks Rb phosphorylation and progression from G1 to S phase: a cytostatic effect 7
Slide 8: G1T38: arrests tumor cells in G1
G1T38: arrests tumor cells in G1 G1T38 blocks proliferation; potentiates tumor cell death when combined with other targeted therapy (e.g. SERD) G1T38 Highly selective CDK4/6 inhibitor with best-in-class potential Differentiated from Ibrance, Kisqali and Verzenio Potential “backbone therapy” for mult
Slide 9: Many cancers do not require CDK4/6 to grow
CDK4/6-independent tumor cell Many cancers do not require CDK4/6 to grow CDK4/6-independent tumors can proliferate even in the presence of a CDK4/6 inhibitor Common CDK4/6-independent tumors include SCLC and TNBC Chemotherapy is typically used to treat these cancers Chemotherapy kills other cells, s
Slide 10: HSPCs are damaged by chemotherapy
HSPC HSPCs are the “reservoir” from which all blood and immune system cells are formed HSPCs are damaged by chemotherapy, causing myelosuppression and immunosuppression, limiting anti-tumor efficacy CDK4/6-independent tumor cell Hematopoietic stem and progenitor cells (HSPCs) require CDK4/6 10
Slide 11: Trilaciclib: transiently arrests HSPCs in G1
CDK4/6-independent HSPC tumor cell Trilaciclib: transiently arrests HSPCs in G1 Short-acting IV therapy for patients with CDK4/6- independent tumors Preserves HSPCs from damage by chemo: myelopreservation Potential to improve tolerability/efficacy of chemotherapy, and chemo/ checkpoint inhibitor com
Slide 12: G1's CDK4/6 inhibitors: broad potential
G1’s CDK4/6 inhibitors: broad potential Drug Tumor type MOA Dosing Combination Initial indications trilaciclib CDK4/6- independent preserves HSPCs, enhances immune system function IV, intermittent chemotherapy and/or checkpoint inhibitor SCLC, TNBC G1T38 CDK4/6- dependent stops tumor cell proliferat
Slide 13: Key advantages of trilaciclib and G1T38
Key advantages of trilaciclib and G1T38 Trilaciclib: a first-in-class approach Rationally designed as a short-acting IV therapy given prior to chemo No known competitor (including PFE, NVS, LLY) PFE, NVS and LLY inhibitors do not have the PK profile required for this setting G1T38: best-in-class pot
Slide 14: G1's development pipeline
G1’s development pipeline Trilaciclib (iv DK4/6i) G1T38 (oral CDK4/6i) 2nd/3rd-line SCLC (+ topotecan) 1st-line SCLC (+ Tecentriq/carbo/etop) Preclinical Phase 1 Phase 2 Phase 3 ER+, HER2- BC (monotherapy) G1T48 (oral SERD) ER+, HER2- BC (+ Faslodex) EGFRm NSCLC (+ Tagrisso) metastatic TNBC (+ gem/c
Slide 15: Key anticipated milestones through 2018
Key anticipated milestones through 2018 Trilaciclib (iv CDK4/6i) G1T38 (oral CDK4/6i) 2nd/3rd-line SCLC (+ topotecan) Phase 2a 1st-line SCLC (+ Tecentriq/ carbo/etop) Phase 2 4Q17 1Q18 2Q18 2H18 ER+, HER2- BC (monotherapy) Phase 1/2a G1T48 (oral SERD) ER+, HER2- BC (+ Faslodex) Phase 1b/2a EGFRm NSC
Slide 16: Trilaciclib development program
TRILACICLIB DEVELOPMENT PROGRAM 16
Slide 17: Opportunity to improve chemotherapy treatment outcomes
Opportunity to improve chemotherapy treatment outcomes and synergize with checkpoint combinations Trilaciclib preserves HSPCs and enhances immune system function during chemotherapy 17
Slide 18: Trilaciclib addresses shortcomings of SOC
Trilaciclib addresses shortcomings of SOC lineage-specific support after damage by chemotherapy accelerates bone marrow exhaustion exacerbates myeloid skewing and chronic lymphopenia Trilaciclib: preserves Current SOC: growth factors and transfusions all blood lineages IV administration before chemo
Slide 19: Rationally designed product profile
Rationally designed product profile Reduce suppression of all hematopoietic lineages by protecting HSPCs from damage by chemotherapy (myelopreservation) Reduce clinically relevant consequences of myelosuppression—e.g. febrile neutropenia (FN)—and reduce overall cost of care from hospitalizations, gr
Slide 20: Trilaciclib value proposition: base case
Trilaciclib value proposition—base case: myelopreservation-only, CDK4/6-independent ~ 1 million patients/year receive chemotherapy (US only) ~ 300,000 patients with CDK4/6-independent tumors eligible for trilaciclib – predominantly CDK4/6-independent: SCLC, TNBC, HPV+ H&N, bladder, cervical, sarcoma
Slide 21: Three ongoing POC trials in extensive-stage SCLC
Three ongoing POC trials in extensive–stage SCLC Setting Combination Phase Total # Patients Primary Endpoints Secondary Endpoints Current Status 1st-line carboplatin (AUC=5) and etoposide (100 mg/m2) 1b: Open label 2a: randomized (1:1), placebocontrolled 96 1b: 19 2a: 77 Myelo preservation: e.g. FN,
Slide 22: 1st-line SCLC Phase 1b/2a trial
1st-line SCLC Phase 1b/2a trial Trilaciclib + etoposide/carboplatin (EP) in patients with newly diagnosed extensive-stage SCLC (PS 0-2) Combination schedule in 21-day cycles – 30 min IV infusion of trilaciclib prior to EP on days 1-3 Completed open-label Phase 1b trial – 19 patients enrolled, 17 eva
Slide 23: Robust myelopreservation, no febrile neutropenia
Robust myelopreservation: mean CBCs above clinically relevant cytopenia thresholds for all blood lineages, no febrile neutropenia cohort 2 (n=9): Phase 2a dose of trilaciclib (240 mg/m2) S = baseline, EC = end cycle 1st-line SCLC complete blood counts (CBCs): no clinically relevant myelotoxicity Dat
Slide 24: 1st-line SCLC: encouraging anti-tumor activity
1st-line SCLC: encouraging anti-tumor activity Data from Rocha Lima et al., ASCO 2017 24
Slide 25: 1st-line SCLC: encouraging anti-tumor activity
1st-line SCLC: encouraging anti-tumor activity Data from Rocha Lima et al., ASCO 2017 25
Slide 26: SCLC 1b/2a trials: conclusions and plans
SCLC 1b/2a trials: conclusions and plans Phase 1b data provides strong evidence of myelopreservation in both first-line and second/third line settings No febrile neutropenia: 51 open-label patients, >250 chemo cycles Improved overall response vs. historical rates in first-line Both studies in random
Slide 27: SCLC: trilaciclib/chemo/checkpoint inhibitor combination trial
SCLC: trilaciclib/chemo/immune checkpoint inhibitor combination trial Trilaciclib: robust immune preservation when given with chemotherapy, preserves lymphocyte numbers/function – Roberts et al., 2017 EORTC-NCI-AACR Compelling preclinical efficacy when trilaciclib/chemo is combined with checkpoint i
Slide 28: Trilaciclib enhances chemo/checkpoint efficacy in tumor model
Trilaciclib enhances chemo/checkpoint efficacy in syngeneic CDK4/6-independent tumor model MC38 tumor growth (median) Trilaciclib has a significant impact on: ORR complete responses survival Repeat experiments demonstrate: reproducibility trilaciclib has no activity as monotherapy (expected with CDK
Slide 29: Expansion to other indications: TNBC
Expansion to other indications: TNBC Significant unmet medical need in triple-negative breast cancer (TNBC) Gemcitabine/carboplatin + trilaciclib in first/second-line metastatic TNBC ~ 90 patient, randomized, open-label Phase 2 trial initiated 1Q17 – primary endpoints: myelopreservation (e.g. FN, tr
Slide 30: G1T38 development program
G1T38 DEVELOPMENT PROGRAM 30
Slide 31: G1T38: only CDK4/6 inhibitor not owned by big pharma
Company CDK4/6 Hormone Signaling Kinase Growth Factors Pathway Inhibitors B-Cell Signaling Novartis Pfizer Lilly Roche AstraZeneca Bayer Takeda Amgen Gilead Sanofi Abbvie Astellas J&J Bristol Myers Celgene Merck G1 Only CDK4/6 inhibitor not owned by big pharma CDK4/6 inhibitors most effective when u
Slide 32: G1T38 differentiation: preclinical and early clinical data
2017 publications – Molecular Cancer Research (Stice et al., preclinical data in prostate cancer) – Oncotarget (Bisi et al., preclinical data in breast cancer and NSCLC) Extensive preclinical validation and differentiation – head-to-head studies with Ibrance (Bisi et al., 2017 Oncotarget) Drug well-
Slide 33: G1T38: backbone therapy for multiple combination regimens
G1T38: backbone therapy for multiple combination regimens—potential development paths Cancer Indication/Line G1T38 with: Rationale Breast HR+/HER2- 1L G1T48 Approval of palbociclib with fulvestrant; extension of mPFS from 4.6 to 9.5 months (PALOMA-3, Turner et al 2015, Cristofanilli et al 2016). G1T
Slide 34: G1T48 development program
G1T48 DEVELOPMENT PROGRAM 34
Slide 35: G1T48: oral SERD, strong strategic fit
G1T48: oral SERD, strong strategic fit Ibrance approved only in combination with an anti-estrogen – first letrozole (aromatase inhibitor), then Faslodex (IM SERD) Multiple companies with oral SERDs in early development G1T48 provides a competitive advantage by controlling economics of a combination
Slide 36: Key anticipated milestones through 2018
Key anticipated milestones through 2018 Trilaciclib (iv CDK4/6i) G1T38 (oral CDK4/6i) 2nd/3rd-line SCLC (+ topotecan) Phase 2a 1st-line SCLC (+ Tecentriq/ carbo/etop) Phase 2 4Q17 1Q18 2Q18 2H18 ER+, HER2- BC (monotherapy) Phase 1/2a G1T48 (oral SERD) ER+, HER2- BC (+ Faslodex) Phase 1b/2a EGFRm NSC
Slide 37: G1 Therapeutics: clinical-stage oncology company
G1 Therapeutics: clinical-stage oncology company Advancing the validated CDK4/6 inhibitor space Three wholly owned drug candidates addressing distinct multi-billion dollar markets Trilaciclib is first-in-class with compelling clinical data; currently in four Phase 2 trials G1T38 has best-in-class po
Slide 38: Appendix: Trilaciclib
APPENDIX: TRILACICLIB Gi THERAPEUTICS
Slide 39: Extensive preclinical and Phase 1a MOA data
Extensive preclinical and Phase 1 MOA data Preclinical validation of trilaciclib demonstrating: – transient and reversible G1 arrest of HSPCs – protection of HSPCs from damage by chemo (myelopreservation) – preservation of bone marrow and immune system function – improved complete blood cell count r
Slide 40: Advantages of trilaciclib vs. GCSF
Advantages of trilaciclib vs. GCSF GCSF Trilaciclib Stimulates granulocyte-specific progenitors after damage by chemo Protects HSPCs from damage by chemotherapy Stimulates granulocyte production only Preserves all hematopoietic lineages Potential to reduce febrile neutropenia (if used prophylactical
Slide 41: Short-acting pharmacology is key
Short-acting pharmacology is key – goal is to rapidly arrest HSPCs in G1, with HSPCs re-entering the cell cycle after chemotherapy – T-cell stimulatory effect is seen with transient CDK4/6 inhibition – prolonged CDK4/6 inhibition is detrimental: blocks T-cell proliferation and causes myelosuppressio
Slide 42: Trilaciclib vs. Ibrance: potency and PK profile
Drug IC50 (uM) CDK4 IC50 (uM) CDK6 IC50 (uM) CDK2-cyclin E IC50 (uM) CDK2-cyclin A CDK2-cyclinE/ CDK4 ratio CDK2-cyclin A/ CDK4 ratio trilaciclib 0.001 0.004 2.51 1.29 2510 1290 Ibrance 0.011 0.015 >10 >10 910 910 Trilaciclib has a very different human PK profile than Ibrance Drug Dose Tmax (h) Cmax
G1 Therapeutics — Investor Presentation (November 2017) on 6ix